AstraZeneca completes $2 billion equity investment in Summit Therapeutics
On 5 October 2026 AstraZeneca closed a $2.0 billion equity investment in Summit Therapeutics, purchasing 108,955 preferred shares convertible at $18.36 per share. The transaction gives AstraZeneca roughly a 12 % stake in Summit’s common stock. Both companies also announced clinical collaborations to test AstraZeneca’s ADCs with Summit’s bispecific antibody ivonescimab.
Why it matters
The funding provides Summit with capital to accelerate ivonescimab Phase III trials, while AstraZeneca gains a strategic foothold in a promising cancer asset and a 12 % equity position. Analysts note that the partnership could expand AstraZeneca’s oncology pipeline and drive future revenue growth for both firms.
Key facts
- 1AstraZeneca invested $2.0 billion in Summit Therapeutics. tradingview.com
- 2The investment consisted of 108,955 preferred shares convertible into common stock at a 1:1,000 ratio, implying a price of $18.36 per share. marketscreener.com
- 3AstraZeneca will hold approximately 12 % of Summit’s outstanding common stock (about 10.6 % on a fully diluted basis). securities.io
- 4The transaction closed on 5 October 2026. securities.io
- 5The companies entered a clinical collaboration to evaluate the ADC sonesitatug vedotin (Sone‑Ve) with ivonescimab in gastrointestinal cancers. tradingview.com
- 6AstraZeneca and Daiichi Sankyo also agreed to collaborate with Summit on the ADC Datroway in multiple tumor types, starting with a Phase III trial in triple‑negative breast cancer. tradingview.com
Summary written by AlphAI from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.